Home › Celgene's VIDAZA (Azacitidine for Injection) Receives Positive CHMP...
 

Keywords :   


Celgene's VIDAZA (Azacitidine for Injection) Receives Positive CHMP...

2015-09-25 15:59:38| Biotech - Topix.net

Expanded indication brings medicine to elderly AML patients who are not eligible for haematopoietic stem cell transplantation and who have >30% myeloblasts in their bone marrow BOUDRY, Switzerland-- -- Celgene International SA rl, a wholly owned subsidiary of Celgene Corporation today announced that that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for an expanded indication of VIDAZAA for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia who are not eligible for haematopoietic stem cell transplantation .

Tags: positive receives injection chmp

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 3
29.06Tropical Storm Beryl Public Advisory Number 3
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 3
29.06Tropical Storm Beryl Forecast Advisory Number 3
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
More »